Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRII - Cell Robotics International, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: ksuave who wrote (214)	5/5/1999 3:37:00 PM
From: WallStBum	Read Replies (1) \| Respond to of 252

Got out awhile back in the runup Richard. I totally agree with you in the l-t aspect; they've got many irons in the fire, ala the news release you just put up. I just wondered if I should wait until the Lasette proves itself as a product that will fly in the diabeties market. They've got a lot of competition in that area. And so I've been quietly waiting for the bottom of this slow slide we've been on for awhile. And frankly, I'm pretty worried about the valuations and volatility of the large-cap mkt as a whole - I'm trying to maybe hold off on some purchases until summer/fall correction season.

To: ksuave who wrote (214)	5/12/1999 2:05:00 PM
From: Chris Block	Read Replies (1) \| Respond to of 252

All: As you may know, CRII currently trades on the SBX Nanocap system, nanocaps.com. The nanocap system is an alternative trading system similar to Instinet and Island, where buyers and sellers can match with or without market makers participation. In addition, AGS Specialist Partners, a well know specialist firm on the American Stock Exchange, has drafted CRII and will be adding liquidity and matching orders on the Nanocap System. This should allow for a decreased spread and the ability to trade in between the spread quoted on the Nasdaq OTC BB. You can gain access to the system by requesting your broker dealer to subscribe or by requesting a referral to a current subscriber. See you on the Nanocap.